Back HCV Treatment

HCV Treatment

AASLD 2017: Mavyret Shows High Cure Rates for HCV Genotype 3 and Cirrhosis

Glecaprevir and pibrentasvir, the 2 drugs in the recently approved Mavyret coformulation, demonstrated high sustained response rates for chronic hepatitis C patients with HCV genotype 3 and for people with liver cirrhosis, according to a pair of reports presented at the 2017 AASLD Liver Meeting last week in Washington, DC.

alt

Read more:

Merck Discontinues Development of Experimental Hepatitis C Drugs

Late last month Merck announced that it was halting further development of 2 investigational hepatitis C therapies. The first is a 3-drug coformulation containing the HCV protease inhibitor grazoprevir, the NS5A inhibitor ruzasvir, and the HCV polymerase inhibitor uprifosbuvir. The second is a 2-drug combo containing ruzasvir and uprifosbuvir.

alt

Read more:

IAS 2017: Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says

HIV, hepatitis B and C, and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College London reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

Janssen Discontinues Hepatitis C Drug Development Program

Janssen Sciences announced last week that it will stop further development of its experimental hepatitis regimen containing AL-335, odalasvir, and simeprevir, as the market is saturated with effective therapies. It will instead focus on hepatitis B, which is seldom cured with existing antiviral medications.

alt

Read more:

Experts Question Cochrane Review of Hepatitis C DAA Treatment

A systematic review of hepatitis C direct-acting antiviral (DAA) studies published by the Cochrane Collaboration has been strongly criticized by doctors and advocates for its conclusion that there is no evidence that the expensive drugs prolong life or reduce liver-related disease in people who achieve a sustained virological response to treatment -- a cure, in current understanding.

alt

Read more: